Original Article

A large case series of travel-related *Mansonella perstans* (vector-borne filarial nematode): a TropNet study in Europe

Francesca Tamarozzi1, PhD,1,†,*, Paola Rodari, MD1,†, Joaquín Salas-Coronas, PhD2, Emmanuel Bottieau, PhD3, Fernando Salvador, PhD4, Manuel Jesús Sorigano-Pérez, MD2, María Isabel Cabeza-Barrera, MD2, Marjan Van Esbroeck, MD3, Begoña Treviño, MD4, Dora Buonfrate1, MD1, and Federico G. Gobbi, PhD1

1Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy, 2Tropical Medicine Unit, Hospital de Poniente, El Ejido, Almería, Spain, 3Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium and 4Tropical Medicine Unit Vall d’Hebron-Drasssanes, Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain

*To whom correspondence should be addressed. Dr Francesca Tamarozzi, Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via don A. Sempereboni 5, 37024 Negrar di Valpolicella, Verona, Italy. Email: francesca.tamarozzi@sacrocuore.it
†These authors contributed equally to this work

Submitted 17 February 2022; Revised 25 March 2022; Editorial Decision 1 April 2022; Accepted 1 April 2022

Abstract

**Background:** Infection with *Mansonella perstans* is a neglected filariasis, widely distributed in sub-Saharan Africa, characterized by an elusive clinical picture; treatment for mansonellosis is not standardized. This retrospective study aimed to describe the clinical features, treatment schemes and evolution, of a large cohort of imported cases of *M. perstans* infection seen in four European centres for tropical diseases.

**Methods:** *Mansonella perstans* infections, diagnosed by identification of blood microfilariae in migrants, expatriates and travellers, collected between 1994 and 2018, were retrospectively analysed. Data concerning demographics, clinical history and laboratory examinations at diagnosis and at follow-up time points were retrieved.

**Results:** A total of 392 patients were included in the study. Of the 281 patients for whom information on symptoms could be retrieved, 150 (53.4%) reported symptoms, abdominal pain and itching being the most frequent. Positive serology and eosinophilia were present in 84.4% and 66.1%, respectively, of those patients for whom these data were available. Concomitant parasitic infections were reported in 23.5% of patients. Treatment, administered to 325 patients (82.9%), was extremely heterogeneous between and within centres; the most commonly used regimen was mebendazole 100 mg twice a day for 1 month. A total of 256 (65.3%) patients attended a first follow-up, median 3 months (interquartile range 2–12) after the first visit; 83.1% of patients having received treatment based on mebendazole and/or doxycycline, targeting *Wolbachia*, became amicrofilaremic, 41.1–78.4% of whom within 12 months from single treatment.

**Conclusions:** Lack of specific symptoms, together with the inconstant positivity of parasitological and antibody-based assays in the infected population, makes the clinical suspicion and screening for mansonellosis particularly difficult. Prospective studies evaluating prevalence of infection in migrants from endemic areas, infection-specific morbidity, presence of *Wolbachia* endosymbionts in *M. perstans* populations from different geographical areas and efficacy of treatment regimens are absolutely needed to optimize the clinical management of infection.

**Key words:** Mansonella perstans, travel, clinical characteristics, treatment, follow-up

© The Author(s) 2022. Published by Oxford University Press on behalf of International Society of Travel Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**Introduction**

*Mansonella perstans* is a filarial parasite of humans that is widely distributed in sub-Saharan Africa, with estimated 100 million people infected and 600 million at risk of infection, while sporadic cases are reported in the Caribbean and in Central and South America.\(^1\)\(^,\)\(^2\) Prevalence rates up to 70–100% were reported among people living in rural villages of some endemic areas in African countries such as Cameroon, Ghana and Uganda.\(^3\)\(^,\)\(^4\) The prevalence of *M. perstans* infection in migrants is largely unexplored and the infection is most likely often overlooked due to its elusive clinical presentation and low index of suspicion. Martelli *et al.*\(^5\) in Italy reported a seroprevalence of ‘filariasis’ of 9.25% in migrants from sub-Saharan Africa, but it is unknown what proportion of these cases were actually caused by *mansonellosis*. In other studies from Spanish tropical diseases hospitals, *M. perstans* was reported in 3.9–10.9% of patients from sub-Saharan Africa having undergone specific parasitological tests to detect microfilariae (mf).\(^6\)\(^–\)\(^10\)

Infective *M. perstans* larvae are transmitted by biting midges of the genus *Culicoides* during their blood meal.\(^7\) The prepatent period is unknown. Adult worms are rarely recovered in humans; occasionally, they have been retrieved from connective tissues in the serous body cavities during surgery or autopsy.\(^11\) Adult females produce mf, which circulate in the blood without circadian periodicity.\(^12\)

Unlike other filariases, mansonellosis is often asymptomatic and, if symptoms are present, they are usually not associated to a specific clinical picture. Non-specific features such as hyperosinophilia, angioedema, Calabar’s swelling-like oedemas, pruritus, fever, headache and pain in synovial/serous cavities are often described in infected patients.\(^11\)\(^–\)\(^13\) However, it is often difficult to attribute the clinical manifestations to *M. perstans* infection, due to the high frequency of co-infections with other parasites.

The diagnosis of *M. perstans* relies on the detection of blood circulating mf; however, it is possible that a proportion of infections may be missed in case of infection with very low or absent microfilaraemia, similar to what occurs in the case of occult (i.e. microfilaremic) loiasis. An antibody-detecting enzyme-linked immunosorbent assay test based on antigens from the related filarial nematode *Acanthocheilonema vitae* is commercially available, but it is not specific for *Mansonella* spp.

The treatment of *M. perstans* infection is not standardized. Prolonged courses of mebendazole, alone or in combination with diethylcarbamazine (DEC) or levamisole (no longer available), appears to have some efficacy.\(^14\)\(^,\)\(^15\) Prolonged treatment with albendazole also seems to be the most effective strategy, while DEC alone has lower efficacy.\(^14\)\(^,\)\(^15\) However, all these approaches often seem to have only partial efficacy, and multiple treatment courses are often needed to reach mf clearance.\(^15\) The presence of the bacterial endosymbiont *Wolbachia* in *M. perstans* is equivocal;\(^16\) therefore, the efficacy of the anti-*Wolbachia* drug doxycycline for the treatment of infected patients is still not conclusively ascertained.\(^15\)\(^–\)\(^18\)

Despite its wide distribution, high prevalence in endemic areas and evident although unspecific clinical manifestations, this infection has so far received very little attention. This study aimed to describe the clinical features, treatment schemes and evolution after treatment of a large cohort of imported cases of *M. perstans* infection seen in four European centres for tropical diseases included in the TropNet network.\(^19\)

**Materials and Methods**

This is an observational, retrospective study, analysing data collected in four TropNet centres (Hospital del Poniente, Almeria, Spain; Institute of Tropical Medicine, Antwerp, Belgium; Vall d’Hebron University Hospital, Barcelona, Spain and IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy). The study protocol was approved by the Ethics Committee for Clinical Studies of Verona and Rovigo Provinces, Italy (study protocol no. 56014).

Data were retrieved from the databases of each centre of all migrant, expatriate or traveller patients attended between 1994 and 2018 who had been travelling or living in an endemic country and were diagnosed with *M. perstans* infection. A case of *M. perstans* infection was defined, for the purpose of this study, as the demonstration of *M. perstans* mf in the blood by microscopy. For each patient, retrieved data concerned demographic information (sex, age, country of birth and of exposure), clinical history [symptoms (available only for the diagnosis time point), treatments, follow-up length] and laboratory examinations [parasitic co-infections at diagnosis, load of *M. perstans* mf/ml based on analysis of the sediment after modified Knott techniques or blood filtration followed by permanent staining for species identification, serology for filariasis (carried out only at diagnosis), presence of eosinophilia and eosinophils/μl]. Eosinophilia was defined as ≥450 eosinophils/μl in peripheral blood. Due to the retrospective and multicentric nature of the study, it was not possible to retrieve details about the methods used (serologic and/or parasitologic and/or molecular) for the diagnosis of parasitic co-infections, which could vary from centre to centre and from period to period within the same centre. De-identified data were collected in an electronic case report form accessible by password only to the investigators of each centre. A descriptive data analysis was performed. Demographic and clinical variables at baseline and at follow-up, as well as percentage change of clinical variables along the follow-up compared to baseline and previous time points, were reported as frequencies and percentages, medians and interquartile range (IQR), or mean and standard deviation (SD), as appropriate.

**Results**

**Baseline cohort characteristics**

A total of 392 patients were included in the study: 129 (32.9%) were diagnosed in Almeria, 99 (25.3%) in Negrar, 93 (23.7%) in Antwerp and 71 (18.1%) in Barcelona. Baseline patients’ characteristics are summarized in Table 1.

Country of exposure to *M. perstans* was known for 390 (99.5%) cases, while these data were missing for two European expatriates [Figure 1]. In migrants, country of exposure coincided with country of birth in all but two patients (n = 262, 99.2%). All tourists and the near totality of expatriates (n = 120, 97.6%) were from Europe; of the three non-European expatriates, one was from Lebanon, one from the Philippines and one from the Democratic Republic of the Congo. In 7 cases, the
country of exposure was not uniquely identifiable since patients resided in two or more endemic countries.

Data on clinical manifestations, either present at the first visit or reported by the patient as reason for seeking medical advice, was extremely heterogeneous between and within centres depending on the periods (Table 2) and encompassed the use of albendazole, diethylcarbamazine (DEC), mebendazole, levamisole, thiabendazole and doxycycline, alone or in combination with each other or with ivermectin. The most commonly used regimen was mebendazole 100 mg twice a day for 1 month. Of the treated patients, 107 (32.9%) had also received concomitant treatment for other parasitic infections with one or more drugs among which ivermectin, DEC, albendazole and praziquantel. Of the remaining 67 patients (17.1%), who did not have a record of treatment specifically administered for filariasis, administered to one or more drugs among which ivermectin, DEC, albendazole, thiabendazole and doxycycline, alone or in combination with each other or with ivermectin. The most

Table 1. Baseline characteristics of patients with M. perstans infection

|                      | ALM N = 129 | NGR N = 99 | ATW N = 93 | BCL N = 71 | All N = 392 |
|----------------------|-------------|-----------|------------|------------|------------|
| **Demographic data** |             |           |            |            |            |
| Male, N (%)          | 116 (89.9)  | 74 (74.8) | 74 (79.6)  | 45 (63.4)  | 309 (78.8) |
| Age, mean ± SD (years) | 29.7 ± 9.5 | 44.3 ± 17.7 | 50.3 ± 16.4 | 39.4 ± 19.6 | 40 ± 17.5 |
| **Type of patient, N (%)** |             |           |            |            |            |
| Migrant              | 129 (100)   | 44 (44.4) | 22 (23.7)  | 69 (97.2)  | 264 (67.3) |
| Expatriate           | 0 (0.0)     | 54 (54.6) | 67 (72.0)  | 2 (2.8)    | 123 (31.4) |
| Tourist              | 0 (0.0)     | 1 (1.0)   | 4 (4.3)    | 0 (0.0)    | 5 (1.3)    |
| **Clinical data**    |             |           |            |            |            |
| Presence of any symptom, N (%) |             |           |            |            |            |
| Yes                  | 44 (34.1)   | 55 (55.5) | 31 (33.3)  | 20 (28.2)  | 150 (34.4) |
| No                   | 85 (65.9)   | 18 (18.2) | 62 (66.7)  | 51 (71.8)  | 131 (30.0) |
| ND                   | 0 (0.0)     | 26 (26.3) | 0 (0.0)    | 0 (0.0)    | 155 (35.6) |
| **Symptoms**, N (% of those with symptoms) |             |           |            |            |            |
| Itching              | 1 (2.3)     | 24 (43.6) | 20 (64.5)  | 11 (55.0)  | 56 (37.3)  |
| Rash                 | 0 (0.0)     | 9 (16.4)  | 6 (19.4)   | 0 (0.0)    | 15 (10.0)  |
| Fatigue              | 0 (0.0)     | 20 (36.4) | 3 (9.7)    | 1 (5.0)    | 24 (16.0)  |
| Asthma-like          | 0 (0.0)     | 3 (5.5)   | 6 (19.4)   | 0 (0.0)    | 9 (6.0)    |
| Abdominal pain       | 43 (97.7)   | 18 (32.7) | 0 (0.0)    | 6 (30.0)   | 67 (44.7)  |
| **Laboratory data**  |             |           |            |            |            |
| Microfilaremia       |             |           |            |            |            |
| Quantification done, N (%) | 8 (6.2)     | 98 (98.9) | 93 (100)   | 71 (100)   | 270 (68.9) |
| mf/ml, median (IQR)  | 120 (50–190)| 13.5 (5–88) | 46 (18–150) | 19 (4–69)  | 26 (7–100) |
| Eosinophilia         |             |           |            |            |            |
| Present, N (%)       | 94 (72.9)   | 77 (77.8) | 52 (55.9)  | 36 (50.7)  | 259 (66.1) |
| Eos/μl if eosinophilia, median (IQR) | 815 (640–1287) | 1060 (750–1800) | 985 (632–1930) | 900 (678–1349) | 970 (645–1521) |
| **Serology**<sup>a</sup> |             |           |            |            |            |
| Performed, N (%)     | 76 (58.9)   | 62 (62.6) | 79 (84.9)  | 1 (1.4)    | 218 (55.6) |
| Result if serology performed |             |           |            |            |            |
| Positive, N (%)      | 59 (77.6)   | 59 (95.2) | 29 (36.7)  | 1 (100)    | 148 (67.9) |
| Borderline, N (%)    | 0 (0.0)     | 0 (0.0)   | 36 (45.6)  | 0 (0.0)    | 36 (16.5)  |
| Negative, N (%)      | 17 (22.4)   | 3 (4.8)   | 14 (17.7)  | 0 (0.0)    | 34 (15.6)  |

ALM, Almeria; NGR, Negrar; ATW, Antwerp; BCL, Barcelona. ND, no data.

<sup>a</sup>Serology was carried out using different assays both between centres and within centres over time; only the final result could be consistently retrieved retrospectively.

**Treatment and follow-up**

Specific treatment for *M. perstans* infection, administered to 325 patients (82.9%), was extremely heterogeneous between and within centres depending on the periods (Table 2) and encompassed the use of albendazole, diethylcarbamazine (DEC), mebendazole, levamisole, thiabendazole and doxycycline, alone or in combination with each other or with ivermectin. The most commonly used regimen was mebendazole 100 mg twice a day for 1 month. Of the treated patients, 107 (32.9%) had also received concomitant treatment for other parasitic infections with one or more drugs among which ivermectin, DEC, albendazole and praziquantel. Of the remaining 67 patients (17.1%), who did not have a record of treatment specifically administered for mansonellosis, 14 (20.9%) had received treatment against other parasites.

Data regarding microfilaremia, eosinophilia and re-treatments along follow-up visits are summarized in Table 3. A total of 136
Figure 1. Country of exposure to *M. perstans* infection by patients’ category (migrants, expatriates, tourists). In seven cases (3 migrants, 2 expatriates, 2 tourists), the country of exposure could also having been a second one. In these cases, the country reported as the most probable is plotted.

Table 2. First treatment regimens for *M. perstans* infection

| Drug(s)                        | Dosage| Length of administration| N patients treated | Centres having used this regimen |
|--------------------------------|-------|-------------------------|--------------------|----------------------------------|
| Albendazole                    | 400 mg/12 h | 3 days | 5 | BCL |
|                                |       | 7 days | 2 | BCL, NGR |
|                                |       | 10 days | 14 | ALM, BCL |
|                                |       | 14 days | 3 | ALM, BCL |
|                                |       | 21 days | 1 | ALM |
|                                | 400 mg/24 h | 10 days | 1 | ALM |
|                                |       | 14 days | 3 | ALM |
| Diethylcarbamazine             | 6 mg/kg/24 h | 21 days | 7 | ALM, ATW, NGR |
| Doxycycline                    | 100 mg/12 h | 6 weeks | 11 | ATW, BCL, NGR |
| Levamisole                     | NR    | NR | 1 | NGR |
| Mebendazole                    | 100 mg/12 h | 3 days | 5 | BCL |
|                                |       | 21 days | 1 | ATW |
|                                |       | 30 days | 127 | ALM, BCL |
|                                |       | NR | 2 | ATW |
|                                | 500 mg/8 h | 14 days | 4 | NGR |
|                                |       | 30 days | 1 | NGR |
| Albendazole + Doxycycline *a*  | 400 mg/12 h + 100 mg/12 h | 14 days +6 weeks | 1 | NGR |
| Albendazole + Ivermectin       | NR    | NR | 1 | NGR |
| Diethylcarbamazine + Ivermectin* | 6 mg/kg/24 h + NR | 21 days + NR | 1 | NGR |
| Mebendazole + Levamisole       | 500 mg/8 h + 150 mg | 14 days +3 days | 110 | ATW, NGR |
| Mebendazole + Doxycycline      | 500 mg/8 h + 100 mg/12 h | 14 days +6 weeks | 23 | NGR |
| Diethylcarbamazine + Thiabendazole *a* | 6 mg/kg/24 h + NR | NR | 1 | NGR |
| No treatment                   | -     | - | 67 | ALM, ATW, BCL, NGR |

ALM, Almeria; NGR, Negrar; ATW, Antwerp; BCL, Barcelona. When drug combination is used, dosage and length of administration are reported for each drug in the same order the drugs are indicated in the first column. NR, not reported.

*a*Drug also possibly administered for another concomitant filarial infection.
(34.7%) patients were lost to follow-up after the first visit, while the remaining 256 (65.3%) attended a further visit between 1 month and 10 years (median 3 months, IQR 2–12). Data on the presence of blood mf at first follow-up were available for 251 of the patients; of these, 153 (60.9%) were amicrofilaremic, while 98 (39%) had still circulating mf. The exact circulating mf density at follow-up was recorded for 69 of these patients who were still microfilaremic, ranging from 1 to 7350 mf/ml (median 12 mf/ml, IQR 3–58), while for 29 patients the only data available were the presence of detectable circulating mf. The changes of mf density from pre-treatment at first follow-up point are shown in Supplementary Figure 1. Figure 2 in particular shows the changes in mf density from pre-treatment for the patients (n = 160) who had their first follow-up time point within 12 months, and were either not treated or treated with the most used schemes, deploying mebendazole (100 mg/12 h for 30 days or 500 mg/8 h for 14 days +/- levamisole) and/or doxycycline (100 mg/12 h for 6 weeks).

Of patients who were treated with these regimens described above only once and having at least one follow-up carried out (n = 160), 133 (83.1%) reached complete mf clearance within the time span (1–106 months) of follow-up. When focusing only on the first year after treatment, cumulatively between 24.6 and 45.9% patients reached amicrofilaremia within 3 months, between 32.9 and 67.6% within 6 months and between 41.1 and 78.4% within 12 months from treatment. Although no formal comparison between treatments could be made, overall the regime containing mebendazole 100 mg/12 h for 30 days seemed to show the best results, with 78.4% of patients attaining amicrofilaremia within 12 months, followed by doxycycline 100 mg/12 h for 6 weeks (+/- mebendazole 500 mg/8 h for 14 days)-containing schemes (65.4% amicrofilaremic at 12 months), and mebendazole 500 mg/8 h for 14 days (41.1% amicrofilaremic at 12 months). Further 13 (8.1%) patients had ≥90% reduction in mf levels at last follow-up attended (1–30 months), 8 (5%) had less prominent reduction by the last follow-up time attended (1–72 months), 3 (1.9%) had mf counts increased at last follow-up (2–3 months) and 3 (1.9%) still had detectable mf at last follow-up (3–7 months), but estimation of change was not possible because mf counts were not recorded. Of note, also among not treated patients having at least one follow-up record (n = 19), 15 (78.9%) reached amicrofilaremia within the time span (2–120 months) of the follow-up [4 (21.1%) within 12 months]. To try evaluating if attained amicrofilaremia was stable or just a result of a temporary fluctuation, we evaluated data on microfilaremia of the 26 patients who were re-evaluated

Table 3. Clinical data and management of patients along follow-up visits

|             | Months after previous time point – median (IQR) | N (% of those attending this follow-up visit per clinical group) | N treated at this follow-up visit – total (% of those attending this follow-up visit) | N treated at this follow-up visit (N of patients for whom this follow-up visit was the last attended (% of each clinical group)) |
|-------------|-----------------------------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| First follow-up | 3 (2–12) | Mf+ Eos+/-/NR | 98 (38.3%) | 41 | 44 (17.19%) | 31 (31.6%) |
|             |        | Mf− Eos+ | 35 (21.5%) | 3 | 36 (65.5%) | 87 (93.6%) |
|             |        | Mf− Eos− | 93 (36.3%) | 0 | 1 (50.0%) | 8 (100%) |
|             |        | Mf NR Eos+ | 2 (0.8%) | 0 | 1 (50.0%) | 0 |
|             |        | Mf−/NR Eos NR/− | 8 (3.1%) | 0 | 0 | 0 |
| Second follow-up | 7 (3–18) | Mf+ Eos+/-/NR | 41 (44.1%) | 19 | 20 (21.51%) | 15 (36.6%) |
|             |        | Mf− Eos+ | 15 (16.1%) | 1 | 13 (86.7%) | 0 |
|             |        | Mf− Eos− | 36 (38.7%) | 0 | 33 (91.7%) | 0 |
|             |        | Mf NR Eos+ | 0 | 0 | 0 | 0 |
|             |        | Mf−/NR Eos NR/− | 1 (1.1%) | 0 | 1 (100%) | 0 |
| Third follow-up | 5 (3–14.5) | Mf+ Eos+/-/NR | 15 (48.4%) | 8 | 8 (25.81%) | 9 (60.0%) |
|             |        | Mf− Eos+ | 1 (3.2%) | 0 | 1 (100%) | 0 |
|             |        | Mf− Eos− | 15 (48.4%) | 0 | 14 (93.3%) | 0 |
|             |        | Mf NR Eos+ | 0 | 0 | 0 | 0 |
|             |        | Mf−/NR Eos NR/− | 0 | 0 | 0 | 0 |
| ≥4th follow-up | 5 (1–7) | Mf+ Eos+/-/NR | 3 (33.3%) | 2 | 2 (28.57%) | 3 (100%) |
|             |        | Mf− Eos+ | 0 | 0 | 0 | 0 |
|             |        | Mf− Eos− | 6 (66.7%) | 0 | 6 (100%) | 0 |
|             |        | Mf NR Eos+ | 0 | 0 | 0 | 0 |
|             |        | Mf−/NR Eos NR/− | 0 | 0 | 0 | 0 |

Eos, eosinophilia; Mf, microfilariae; NR, not reported.
Figure 2. Percentage change in mf/ml blood at first follow-up when performed within 12 months compared to pre-treatment levels in patients having microfilaremia assessed at both time points (n = 160) not treated or treated with selected regimes. Each symbol represents an individual patient at his/her first follow-up. First follow-up was performed at variable times (X axis) within the first 12 months for the depicted 160 patients. When mf/ml were not evaluated, but only the presence/absence of circulating mf was reported, persistence presence of mf at follow-up was indicated as 0% change (* box). No mf detectable at follow-up is indicated as −100% change. Blue dots = treatment with mebendazole 100 mg/12 h for 30 days. Red squares = treatment with mebendazole 500 mg/8 h for 14 days + − levamisole 150 mg for 3 days. Green triangles = treatment with doxycycline 100 mg/12 h for 6 weeks. Pink diamonds = treatment with mebendazole 500 mg/8 h for 14 days followed by doxycycline 100 mg/12 h for 6 weeks. Black cross = no treatment.

at least once after the first time point in which amicrofilaremia was observed (median 15 months after amicrofilaremia was observed, IQR 7.7–16.7). Only in two (7.7%) of these cases, both having attained amicrofilaremia after treatment, blood mf could be detected again at a later time point (6 and 36 months after the previous amicrofilaremic time point).

At first follow-up, eosinophilia was still present in 86 (49.1%) of the 175 patients who had eosinophilia at diagnosis and who had eosinophilia re-assessed; in these patients, eosinophils count had reduced for the majority of them (n = 57, 66.3%; reduction between 1.8 and 92%), while eosinophils/μl had increased between 5.2 and 471.1% in the remaining 29 patients (33.7%). Of the 116 patients who had eosinophilia at diagnosis and who attained amicrofilaremia at first follow-up, 52 (44.8%) still had eosinophilia at this time point; of note, 2 of the 37 patients (5.4%) who did not have eosinophilia at diagnosis had developed eosinophilia at first follow-up notwithstanding clearance of microfilaremia. When considering the whole cohort, independently of achievement of amicrofilaremia at first follow-up, of the 133 patients with no eosinophilia at diagnosis, 8 (6%) developed it during the follow-up, 62 remained with eosinophil counts within normal range and for 7 patients these data were not recorded (56 were lost to follow-up).

Further follow-up visits were attended by decreasing number of patients: 93 (23.7% of originally diagnosed patients; 36.3% of those attending a first follow-up) attended a second visit; 31 a third one; 7 a fourth one and 2 even a fifth one. Overall, 163 patients attended only one follow-up visit, 62 attended two follow-up visits, 24 attended three and 9 attended four or more follow-up visits. Between 16 and 42% of patients lost to follow-up at each follow-up visit were still microfilaremic at the last evaluation. After the first follow-up, only 44 patients (17.2% of patients having attended a first follow-up visit) were re-treated due to persistent microfilaremia and/or eosinophilia. Re-treatment was with the same regime as the first one in 22 (50%) of cases.

Discussion
Infection with M. perstans is the most neglected filariasis, characterized by an elusive clinical picture. No guidelines are available for its treatment. Outside endemic areas, a number of reference centres for tropical diseases have described the clinical characteristics and management of large cohorts of patients with M. perstans infection, in the attempt to better frame its clinical management.16–18,28
From the clinical aspect, the results of our study, partly including data presented in\textsuperscript{16–18,28}, are in line with previous observations. They confirm that (i) infection is largely asymptomatic (at least one-third of clinical records examined in our study reported that the patients did not complain of symptoms); (ii) when symptoms are reported these are non-specific (with abdominal pain and itching being the most frequently reported); (iii) eosinophilia is inconsistently present (in little over half of cases in our study) and, when present, generally is in the mild to moderate range; (iv) microfilaremia is generally high (based on data from patients in whom number of mf/ml was quantified) and (v) serology for filariasis is positive or borderline in the majority, but not the totality of cases. The lack of specific symptoms, together with the frequent but inconsistent positivity to serology tests for filariasis (84\% of cases in our study, which included only patients with mf in blood), make the clinical suspicion and screening for perstans mansoni nnesis particularly difficult.

No consensus exists on the treatment of mansoni nnesis: treatment schemes for M. perstans vary from centre to centre and within centres, and some clinicians may even opt not to treat the infection if the patient is completely asymptomatic. The uncertainty on the morbidity caused by mansoni nnesis is presumably at the basis of this attitude. The presence of Wolbachia endosymbionts in M. perstans, and therefore the efficacy of the anti-Wolbachia drug doxycycline for the treatment of infected patients, is also still uncertain.\textsuperscript{21} Initial studies conducted in Gabon and Uganda did not detect Wolbachia in M. perstans.\textsuperscript{22} However, the endosymbiont was detected in M. perstans in other studies from Mali,\textsuperscript{21,24} Gabon\textsuperscript{25} and Ghana.\textsuperscript{26} Two trials of doxycycline treatment, carried out in Mali and Ghana,\textsuperscript{24,26} showed clearance of microfilaremia in a significant proportion of participants in the months after treatment, as well as depletion of Wolbachia bacteria from circulating mf. The recent identification in Gabon of a potentially new species or genotype of Mansonella, microscopically undistinguishable from M. perstans, called Mansonella sp. ‘DEUX’,\textsuperscript{29,30} with similarly inconsistent retrieval of Wolbachia, adds further complexity to the picture. No clinical trial comparing different treatment schemes has been implemented for this infection. In accordance with previous publications,\textsuperscript{16,17} the results of our study show that a high proportion of patients achieved parasitological cure (assessed by attaining microfilaremia) after one single treatment and within the first year after treatment, but also, although in apparently lower proportions, spontaneously. Although too few patients had additional follow-up visits after the one where amicrofilaremia was first observed, and at very different intervals, to conclusively evaluate whether microfilaremia was permanent or just a result of a temporary fluctuation of blood mf levels, from our data it seems that amicrofilaremia might have been stably achieved in the majority of cases. Overall, the regime containing mebendazole 100 mg/12 h for 30 days seemed to show the best results, followed by doxycycline (4/– mebendazole 500 mg/8 h for 14 days)-containing schemes, and mebendazole 500 mg/8 h for 14 days. However, the heterogeneity in treatment schedules and follow-up time points at which the patients were re-evaluated prevents any conclusion on the comparative efficacy of different treatment schemes. In addition, even outside endemic areas where re-infection cannot occur and confound efficacy results, it is difficult to assess parasitological clearance. Indeed, there are no markers/tests that can detect the adult worms, the presence of which, at present, can only be revealed by the detection of circulating mf. Thus, efficacy evaluations can be only based on the detection (or lack thereof) of circulating mf and ancillary laboratory data (eosinophils, anti-filarial antibodies).\textsuperscript{11} In our study, no serology results were available for the follow-up time points and no attempt was made to infer parasitological cure on the basis of presence/absence of eosinophilia in addition to amicrofilaremia. Indeed, data obtained at first follow-up showed that nearly half of patients still had eosinophilia while a small percentage even developed new eosinophilia notwithstanding having cleared blood mf. Treatment efficacy is hence not easily assessed, likely requires follow-up in the absence of treatment to observe changes in laboratory parameters which may occur with some delay, and novel markers of infection are much needed. In this study, achievement of amicrofilaremia spontaneously in a large proportion of untreated patients could reflect spontaneous cure, for example due to natural death of adult worms, or failure to detect persistent infection due to low/ﬂuctuating levels of circulating mf. Similarly, the persistence of circulating mf for months after treatment may not necessarily reflect the concomitant presence of viable fertile adult worms.\textsuperscript{1,11} In agreement with the suggestion of Gobbi and colleagues,\textsuperscript{24} an observation of 12–15 months after treatment would probably be worth before evaluating the need of re-treatment, to both avoid overtreatment and observe if apparent parasitological cure is a stable condition. However, this is often very difficult to implement since the migrant population, most affected by M. perstans, is highly mobile and therefore generally poorly compliant with long-term follow-up. Finally, the relative morbidity caused by parasite adults and mf is not known, which could inform the need to target only adults or also mf with specific treatment.

This study has several limitations which prevent performing a more elaborated analysis of data and driving stronger conclusions, due to its retrospective design, extreme heterogeneity of data (laboratory assays, treatment regimens and their implementation on individual patients, follow-up time points and analyses performed at each time point), presence of gaps in data completeness, non-systematic/inconsistent laboratory follow-up, absence of information regarding re-exposure between visits and high rate of loss to follow-up. This latter finding is not surprising due to the fact that data come from records of routine clinical practice (i.e. with non-standardized procedures in the context of a study protocol) on a migrant population, which is highly mobile and generally complying poorly with follow-up visit for a variety of reasons.

The retrospective design of this and previous studies, together with the high frequency of co-infections with other parasites, hampers a more precise definition of the signs and symptoms caused by mansoni nnesis, which might be erroneously considered as a relatively benign condition, as it happened with loiasis, for which only recently was demonstrated a relevant impact on morbidity and mortality.\textsuperscript{32,33} Prospective studies evaluating infection-specific morbidity, together with systematic, multicentric surveys estimating the prevalence of infection in migrants from endemic areas, are required to quantify the burden of infection and the need of screening and treatment interventions. Likewise, placebo-controlled studies comparing treatment regimens for M. perstans (and Mansonella spp. ‘DEUX’) infection are absolutely needed.
to rationalize the clinical management (outside transmission areas) and control (in endemic areas) of this infection, since analysis of retrospective data collected during routine clinical activity cannot provide conclusive answers. In this field, the presence of Wolbachia in *M. perstans* populations from different geographical origins and long-term efficacy of doxycycline, more or less combined with mebendazole, in international travellers also need to be investigated.

**Supplementary data**

Supplementary data are available at JTM online.

**Data availability statement**

Data are available at https://zenodo.org/record/6122558

**Author contributions**

F.G.G. conceived the study. F.G.G., P.R., J.S.-C., E.B., F.S., M.J.S.-P., M.I.C.-B., M.V.E. and B.T. collected the data. F.T. analysed the data. F.T., P.R. and F.G.G. wrote the manuscript. F.G.G., J.S.-C., E.B., F.S., F.T. and D.B. critically revised the manuscript for its scientific content. All authors approved the final version of the manuscript.

**Acknowledgements**

We are thankful to Monica Degani and Stefano Tais for their invaluable work and expertise in the diagnosis of parasitic infections at the Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy, and tireless support for data extraction.

**Funding**

The publication of this study was funded by Italian Ministry of Health Fondi Ricerca Corrente–L2 to IRCCS Sacro Cuore Don Calabria Hospital.

**Conflict of interest**

None declared.

**Ethical statement**

The study protocol was approved by the Ethics Committee for Clinical Studies of Verona and Rovigo Provinces, Italy (study protocol no. 56014).

**References**

1. Simonsen PE, Onapa AW, Asio SM. *Mansonella perstans* filariasis in Africa. *Acta Trop* 2011; 120:5109–20.
2. Ta-Tang TH, Crainey JL, Post RJ, Luz SL, Rubio JM. Mansoellogenesis: current perspectives. *Res Rep Trop Med* 2018; 9:9–24.
3. Wanji S, Amvongo-Adjia N, Koudou B, Njouendou AJ et al. Cross-reactivity of filarial ICT cards in areas of contrasting endemicity of *Loa loa* and *Mansonella perstans* in Cameroon: implications for shrinking of the lymphatic filariasis map in the central African region. *PLoS Negl Trop Dis* 2015; 9:e0004184.
4. Debrah LB, Naushch N, Opoku VS, Owusu W et al. Epidemiology of *Mansonella perstans* in the middle belt of Ghana. *Parasit Vectors* 2017; 10:15.
5. Asio SM, Simonsen PE, Onapa AW. Mansonella perstans filariasis in Uganda: patterns of microfilaraemia and clinical manifestations in two endemic communities. *Trans R Soc Trop Med Hyg* 2009; 103:266–73.
6. Martelli G, Di Girolamo C, Zamarchi L, Angheben A et al. Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study. *Clin Microbiol Infect* 2017; 23:335.e1–5.
7. Cobo F, Salas-Coronas J, Cabezás-Fernández MT, Vraquez-Villega J et al. Infectious diseases in immigrant population related to the time of residence in Spain. *J Immigr Minor Health* 2016; 18:8–15.
8. Serre Delcor N, Maruri BT, Arandes AS, Claveria Guiu I et al. Infectious diseases in sub-Saharan immigrants to Spain. *Am J Trop Med Hyg* 2016; 94:750–6.
9. Salas-Coronas J, Cabezás-Fernández MT, Lozano-Serrano AB, Soriano-Perez MJ et al. Newly arrived African migrants to Spain: epidemiology and burden of disease. *Am J Trop Med Hyg* 2018; 98:319–25.
10. Boga JA, Casado L, Fernández-Suarez J, Moran N et al. Screening program for imported diseases in immigrant women: analysis and implications from a gender-oriented perspective. *Am J Trop Med Hyg* 2020; 103:480–4.
11. Baird JK, Neafie RC, Lanoie L, Connor DH. Adult *Mansonella perstans* in the abdominal cavity in nine Africans. *Am J Trop Med Hyg* 1987; 37:578–84.
12. Asio SM, Simonsen PE, Onapa AW. Analysis of the 24-h microfilarial periodicity of *Mansonella perstans*. *Parasitol Res* 2009; 104:945–8.
13. Adolph PE, Kagan IG, McQuay RM. Diagnosis and treatment of Acanthocheilonema perstans filariasis. *Am J Trop Med Hyg* 1962; 11:76–88.
14. Baird JK, Neafie RC, Connor DH. Nodules in the conjunctiva, bung-eye, and bulge-eye in Africa caused by *Mansonella perstans*. *Am J Trop Med Hyg* 1988; 38:553–7.
15. Bregani ER, Rovellini A, Mbaindou M, Magnini MG. Comparison of different anthelminthic drug regimens against *Mansonella perstans* filariasis. *Trans R Soc Trop Med Hyg* 2006; 100:458–63.
16. Bottieau E, Huits R, Van Den Broucke S, Maniewski U et al. Human filariasis in travelers and migrants: a retrospective 25-year analysis at the Institute of Tropical Medicine, Antwerp, Belgium. *Clin Infect Dis* 2021; eia751.
17. Cobo F, Cabezás-Fernández MT, Salas-Coronas J, Cabeza-Barrera MI et al. Filariaisis in sub-Saharan migrants attended in a health area of southern Spain. *Parasitol Vectors* 2012; 7506.
18. Puente S, Lago M, Subirats M, Sanz-Esteban I et al. Imported *Mansonella perstans* infection in Spain. *Infect Dis Poverty* 2020; 9:105.
19. Van Hoegaarden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariais due to *Loa loa* and *Mansonella perstans*. *Am J Trop Med Parasitol* 1987; 38:75–82.
20. Lipani F, Caramello P, Biglino A, Sacchi C. Albendazole for the treatment of *Mansonella perstans* filariasis. *Trans R Soc Trop Med Hyg* 1997; 1:221.
21. Hoerauf A. *Mansonella perstans*—the importance of an endosymbiont. *N Engl J Med* 2009; 361:1502–4.
22. Grobusch MP, Kombila M, Autenrieth I, Mehlhorn H, Kremser PG. No evidence of Wolbachia endosymbiosis with *Loa loa* and *Mansonella perstans*. *Parasitol Res* 2003; 90:405–8.
23. Keiser PB, Coulibaly Y, Kubočík J, Diallo AA et al. Molecular identification of Wolbachia from the filarial nematode Mansonella perstans. Mol Biochem Parasitol 2008; 160:123–8.
24. Coulibaly YI, Dembele B, Diallo AA, Lipner EM et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 2009; 361:1448–58.
25. Gehringer C, Kreidenweiss A, Flamen A, Antony JS et al. Molecular evidence of Wolbachia endosymbiosis in Mansonella perstans in Gabon, Central Africa. J Infect Dis 2014; 210:1633–8.
26. Batsa Debrah L, Phillips RO, Pfarr K, Klarmann-Schulz U et al. The efficacy of doxycycline treatment on Mansonella perstans infection: an open-label, randomized trial in Ghana. Am J Trop Med Hyg 2019; 101:84–92.
27. http://tropnet.eu/ 14 February 2022, date last accessed.
28. Gobbi F, Beltrame A, Buonfrate D, Staffolani S et al. Imported infections with Mansonella perstans nematodes, Italy. Emerg Infect Dis 2017; 23:1539–42.
29. Mourembou G, Fenollar F, Lekana-Douki JB, Ndjoyi Mbiguino A et al. Mansonella, including a potential new species, as common parasites in children in Gabon. PLoS Negl Trop Dis 2015; 9:e0004155.
30. Sandri TL, Kreidenweiss A, Cavallo S, Weber D et al. Molecular epidemiology of Mansonella species in Gabon. J Infect Dis 2021; 223:287–96.
31. Gobbi F, Tamarozzi F, Buonfrate D, Rodari P et al. Laboratory parameters after treatment for Loa loa and Mansonella perstans: the experience of a single referral center for tropical diseases in a non-endemic area. Am J Trop Med Hyg 2019; 100:914–20.
32. Veletzky L, Hergeth J, Stelzl DR, Mischlinger J et al. Burden of disease in Gabon caused by loiasis: a cross-sectional survey. Lancet Infect Dis 2020; 20:1339–46.
33. Chesnais CB, Takougang I, Paguélé M, Pion SD, Boussinesq M. Excess mortality associated with loiasis: a retrospective population-based cohort study. Lancet Infect Dis 2017; 17:108–16.